MEDANTA share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on MEDANTA. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for MEDANTA is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for MEDANTA is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

MEDANTA sits in Healthcare (mid cap), indicative market cap ~35,481 cr (indicative), ISIN INE474Q01031. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on GLOBAL HEALTH LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on MEDANTA is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, GLOBAL HEALTH LIMITED sits in the Watchlist tier with a setup score of 96/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 14 MEDANTA earnings calls going back to 2023-02-28, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

GLOBAL HEALTH LIMITED reported a net profit of Rs 142 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +39.7% year on year. The figure is from the company's official NSE filing.

GLOBAL HEALTH LIMITED reported revenue of Rs 1,159 cr for Q4 FY26. That is +24.5% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives GLOBAL HEALTH LIMITED's Q4 FY26 result a Result Pulse of 97 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Global Health Ltd's two most material recent disclosures are an investor meet dated 24 Jul 2026, "Schedule of meet", and a regulatory dated 15 Jul 2026, "Certificate under SEBI (Depositories and Participants)…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Global Health Ltd filed a dividend disclosure on 14 May 2026, filed as "Board of Directors at its meeting held on May 14, 2026, recommended…". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Global Health Ltd's most recent board-meeting disclosure on record dated 14 May 2026 reads "Board Meeting to be held on 14-May-2026 to consider and approve the…". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.